Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says

MT Newswires Live

05/16

Wave Life Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.

The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.

The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.

Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.

Shares of the company were down 2.6% in Friday trading.

Price: 6.72, Change: -0.18, Percent Change: -2.61

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635034943"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635034943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635034943?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-16 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635034943","market":"hk","top_or_hot":-1,"title":"Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.</p><p>The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.</p><p>The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.</p><p>Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.</p><p>Shares of the company were down 2.6% in Friday trading.</p><p>Price: 6.72, Change: -0.18, Percent Change: -2.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-16 02:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.</p><p>The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.</p><p>The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.</p><p>Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.</p><p>Shares of the company were down 2.6% in Friday trading.</p><p>Price: 6.72, Change: -0.18, Percent Change: -2.61</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635034943","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635034943","pubTimestamp":1778870414,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wave Life Sciences  is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd","BK4139":"生物科技","BK4161":"工业机械","ATS":"ATS Corp.","BK4007":"制药","RNA":"Atrium Therapeutics","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4505":"高瓴资本持仓"},"translate_title":"Wedbush表示，Wave Life Sciences ATS数据可以支持RNA编辑平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1.5,"WVE":1,"ATS":1.5},"content_text":"Wave Life Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}